Company intelligence / Profile preview

Verdemed

Toronto, Ontario, Canadaverdemed.com ↗

Ownership: Private
Development stage: Other

Overview

Verdemed develops and commercializes cannabis-based pharmaceutical products—primarily CBD isolates and "Epidiolex me-too" formulations—for the healthcare sector in Latin America. The company has achieved regulatory approvals for several products in Brazil, with plans to expand its portfolio further. Sales have begun, with significant growth projected as additional authorizations are secured. The company's strategy centers on adapting proven North American/European cannabinoid medications to meet unmet clinical needs across Latin American markets.

Therapeutic areas: NeurologyOther
Modalities: Small moleculeBiologicCannabinoid-based pharmaceuticals
Industry: Biotech

Partnerships

Strategic alliances with global cannabis pharmaceutical companies for LATAM market entry planned/in progress

Beyond the preview

Go deeper on Verdemed.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Verdemed.

Explore the full profile